ReviewCancer management and research2022

Optimal Choice of Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer: Clinical Insights.

Mairi W Lucas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.